Salgado Teresa M, Mackler Emily, Severson Jane A, Lindsay Jamie, Batra Peter, Petersen Laura, Farris Karen B
University of Michigan College of Pharmacy, 428 Church St., Ann Arbor, MI, USA.
Michigan Oncology Quality Consortium, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd., SPC 2800, Building 14, G210-30, Ann Arbor, MI, 48109, USA.
Support Care Cancer. 2017 Jun;25(6):1797-1807. doi: 10.1007/s00520-017-3584-0. Epub 2017 Jan 20.
The Michigan Oncology Quality Consortium (MOQC) is a continuous quality improvement collaborative seeking to improve oncology care in Michigan, including for patients taking oral chemotherapy. The aim of this study was to assess the relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics to inform future oncology care.
A multicenter cross-sectional observational study was conducted using an online survey to examine patient activation (patient activation measure, PAM), health literacy, symptom burden (Edmonton Symptom Assessment System, ESAS), confidence to self-manage side effects (fatigue, nausea, and diarrhea), and adherence to oral oncolytics. Inclusion criteria were patients taking an oral oncolytic for at least 1 month. Bivariate analyses and logistic regression were performed to evaluate relationships between the variables.
A total of 125 respondents, mean (SD) age 66.2 (13.6), 57.7% female, and 95.1% Caucasian completed the survey. The mean (SD) PAM score was 65.0 (18.0). Confidence to manage fatigue, nausea, and diarrhea was associated with higher activation, and confidence to self-manage fatigue and diarrhea were associated with higher health literacy. About 30% of participants reported some level of non-adherence to oral oncolytics, and those who experienced side effects (Fisher's exact test p = 0.033) and with shorter length of therapy (t test p = 0.027) were significantly more likely to be non-adherent.
These findings show that there is room for improvement across practices involved with MOQC with regard to supporting patients taking oral oncolytics. Patients will need to improve their activation levels, and oncology clinics will need to create new workflows in order to enhance self-care management ability for patients taking oral oncolytics.
密歇根肿瘤质量联盟(MOQC)是一个持续质量改进协作组织,致力于改善密歇根州的肿瘤护理,包括接受口服化疗的患者。本研究的目的是评估患者激活度、自我管理副作用的信心以及口服肿瘤药物依从性之间的关系,为未来的肿瘤护理提供参考。
采用在线调查进行多中心横断面观察性研究,以检查患者激活度(患者激活度测量量表,PAM)、健康素养、症状负担(埃德蒙顿症状评估系统,ESAS)、自我管理副作用的信心(疲劳、恶心和腹泻)以及口服肿瘤药物的依从性。纳入标准为服用口服肿瘤药物至少1个月的患者。进行双变量分析和逻辑回归以评估变量之间的关系。
共有125名受访者完成了调查,平均(标准差)年龄为66.2岁(13.6岁),女性占57.7%,白种人占95.1%。平均(标准差)PAM评分为65.0(18.0)。管理疲劳、恶心和腹泻的信心与更高的激活度相关,自我管理疲劳和腹泻的信心与更高的健康素养相关。约30%的参与者报告有一定程度的口服肿瘤药物不依从情况,经历副作用的患者(Fisher精确检验p = 0.033)和治疗时间较短的患者(t检验p = 0.027)不依从的可能性显著更高。
这些发现表明,在支持接受口服肿瘤药物治疗的患者方面,MOQC所涉及的各医疗机构仍有改进空间。患者需要提高其激活水平,肿瘤诊所需要创建新的工作流程,以增强接受口服肿瘤药物治疗患者的自我护理管理能力。